Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.

Download
Citations
Altmetric
Author
McClure, T; Cui, W; Asadi, K; John, T; Testro, ADate
2020-09Source Title
BMJ Open GastroenterologyPublisher
BMJUniversity of Melbourne Author/s
Testro, AdamAffiliation
Medical EducationMetadata
Show full item recordDocument Type
Journal ArticleCitations
McClure, T., Cui, W., Asadi, K., John, T. & Testro, A. (2020). Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.. BMJ Open Gastroenterol, 7 (1), pp.e000487-e000487. https://doi.org/10.1136/bmjgast-2020-000487.Access Status
Open AccessOpen Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867Abstract
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References